GlassScriptPhysician profile
Kimberly Verhoef
NPI 1922097484
$1,368.56
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $835 · 2020: $289 · 2021: $196 · 2022: $48.96.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $408.90 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $119.00 | 2019 | |
| Abbvie INC. | $109.76 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $104.36 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $89.64 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $83.37 | 2019-2021 | |
| Bausch Health US, LLC | $74.22 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $71.57 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $64.67 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $37.86 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $36.48 | 2021 | |
| Lundbeck LLC | $36.37 | 2019-2020 | |
| Neos Therapeutics, LP | $33.64 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $26.82 | 2019 | |
| Owp Pharmaceuticals, INC. | $22.16 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $13.43 | 2019 | |
| Vanda Pharmaceuticals INC. | $12.82 | 2019 | |
| Neurocrine Biosciences, INC. | $11.83 | 2019 | |
| Neuronetics, INC. | $11.66 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Verhoef listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.